DLB and PDD boundary issues: Diagnosis, treatment, molecular pathology, and biomarkers.
Lippa, C F. MD; Duda, J E. MD; Grossman, M MD; Hurtig, H I. MD; Aarsland, D MD; Boeve, B F. MD; Brooks, D J. MD; Dickson, D W. MD; Dubois, B MD; Emre, M MD; Fahn, S MD; Farmer, J M.; Galasko, D MD; Galvin, J E. MD, MPH; Goetz, C G. MD; Growdon, J H. MD; Gwinn-Hardy, K A. MD; Hardy, J PhD; Heutink, P PhD; Iwatsubo, T MD, PhD; Kosaka, K MD, PhD; Lee, V M.-Y. PhD; Leverenz, J B. MD; Masliah, E MD; McKeith, I G. MD; Nussbaum, R L. MD; Olanow, C W. MD; Ravina, B M. MD; Singleton, A B. MD, PhD; Tanner, C M. MD, PhD; Trojanowski, J Q. MD, PhD; Wszolek, Z K. MD; for the DLB/PDD Working Group *
68(11):812-819, March 13, 2007.
(Format: HTML, PDF)
mdash;: For more than a decade, researchers have refined criteria for the diagnosis of dementia with Lewy bodies (DLB) and at the same time have recognized that cognitive impairment and dementia occur commonly in patients with Parkinson disease (PD). This article addresses the relationship between DLB, PD, and PD with dementia (PDD). The authors agreed to endorse "Lewy body disorders" as the umbrella term for PD, PDD, and DLB, to promote the continued practical use of these three clinical terms, and to encourage efforts at drug discovery that target the mechanisms of neurodegeneration shared by these disorders of [alpha]-synuclein metabolism. We concluded that the differing temporal sequence of symptoms and clinical features of PDD and DLB justify distinguishing these disorders. However, a single Lewy body disorder model was deemed more useful for studying disease pathogenesis because abnormal neuronal [alpha]-synuclein inclusions are the defining pathologic process common to both PDD and DLB. There was consensus that improved understanding of the pathobiology of [alpha]-synuclein should be a major focus of efforts to develop new disease-modifying therapies for these disorders. The group agreed on four important priorities: 1) continued communication between experts who specialize in PDD or DLB; 2) initiation of prospective validation studies with autopsy confirmation of DLB and PDD; 3) development of practical biomarkers for [alpha]-synuclein pathologies; 4) accelerated efforts to find more effective treatments for these diseases.
(C)2007 American Academy of Neurology